News of Bahrain
Bahrain26 August 20212 min read

Sinopharm less effective in elderly vaccinated Covid positive patients: Bahrain

TDT | Manama The Daily Tribune – www.newsofbahrain.com The Sinopharm vaccine appeared to be less effective in elderly vaccinated people who are Covid positive, according to data from a study conducted in Bahrain. The study had found that the percentage of deaths among all P

Editorial Team Legacy

Published 26 August 2021, 8:00 · Updated 21:45

Link copied
Sinopharm less effective in elderly vaccinated Covid positive patients: Bahrain

TDT | Manama

The Daily Tribune – www.newsofbahrain.com

The Sinopharm vaccine appeared to be less effective in elderly vaccinated people who are Covid positive, according to data from a study conducted in Bahrain.

The study had found that the percentage of deaths among all PCR positive post-vaccination Covid-19 cases among recipients of the Sinopharm vaccine was 0.46% (i.e, 112 deaths) versus 0.15% for Pfizer/BioNtech (i.e., three deaths) and 0.03% for AZ/Covishield (one death).

The authors have however concluded that the four vaccines were effective in reducing all four outcomes (infections, hospitalizations, ICU admissions and deaths) in vaccinated compared to unvaccinated individuals, prior to, and during the period when the Delta variant became dominant in the country.

The data published by Research Square notes that after censoring early vaccine recipients of Sinopharm vaccine, compared to Pfizer/BionTech recipients, individuals vaccinated with Sinopharm had a higher risk of post-vaccination infections, hospitalizations, ICU admissions and deaths, especially in those above 50 years old.

The overall findings support the value of vaccination in preventing COVID-19 related events even with the advent of the Delta variant. The data support the urgent need to expand vaccination access around the world, and may serve to guide the choice of vaccines in the context of the Delta variant.

Join the conversation

Sign in to leave a comment. Every comment is reviewed before it goes live.

No comments yet. Start the conversation.